Resverlogix Corp. (TSE:RVX – Get Free Report) reached a new 52-week low during trading on Monday . The company traded as low as C$0.05 and last traded at C$0.06, with a volume of 11000 shares changing hands. The stock had previously closed at C$0.06.
Resverlogix Price Performance
The stock’s 50-day simple moving average is C$0.06 and its 200 day simple moving average is C$0.06. The company has a market cap of C$16.33 million, a price-to-earnings ratio of -1.20 and a beta of 0.78.
Resverlogix Company Profile
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Further Reading
- Five stocks we like better than Resverlogix
- How to Invest in the Best Canadian Stocks
- 3 Technologies to Challenge NAND Flash Dominance in AI
- 3 Tickers Leading a Meme Stock Revival
- Is Zoom Video Stock Getting Too Cheap to Pass Up?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Packaging Corporation of America: Buy The Dip
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
